Trial
NCT06171789
PRO1107 in Patients With Advanced Solid Tumors
Phase ITERMINATEDSAFETYConfidence: MEDIUM
Sponsor
Genmab
Collaborators
—
Condition
Endometrial Cancer
Intervention
GEN1107
Why stopped
Genmab has decided to discontinue the clinical development of GEN1107 as the overall benefit-risk profile no longer supports continuation
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2026-06-01